Highlights

Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation

Banner for NCI-Sponsored Pharmacogenomics and Pharmacoepidemiology Workshops

The Trans-NCI Pharmacogenomics and Pharmacoepidemiology Working Group (PPWG) and Division of Cancer Control and Population Sciences (DCCPS) sponsored the workshop “Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation” on July 21, 2009, on the NIH Campus, Bethesda, MD. The meeting brought together experts from various disciplines in the cancer and pharmacology research communities to identify infrastructures, resources, and pressing clinical issues, and discuss recommendations and priorities to advance cancer pharmacoepidemiology and pharmacogenomics research.

The workshop was organized by Andrew N. Freedman, Ph.D., Chair of the PPWG, and Chief, Clinical and Translational Epidemiology Branch (CTEB) in the Epidemiology and Genetics Research Program (EGRP), DCCPS, and Leah B. Sansbury, Ph.D., M.S.P.H., Co-Chair of PPWG’s Population Sciences Sub-Group, and Program Director, CTEB.

Commentary summarizing the 2009 Workshop and its recommendations:

AGENDA
Tuesday, July 21, 2009
7:30 a.m. – 5:45 p.m.
Natcher Auditorium
NIH
Bethesda, MD
7:30 a.m. – 8:00 a.m. Registration
8:00 a.m. – 8:30 a.m. Welcome and Introduction

James H. Doroshow, M.D., Director, Division of Cancer Treatment and Diagnosis (DCTD), NCI. [PDF, HTML]

Andrew N. Freedman, Ph.D., Chief, Clinical and Translational Epidemiology Branch, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences (DCCPS), NCI. [PDF, HTML]
8:30 a.m. – 8:45 a.m. Workshop Overview and Objectives

Leah B. Sansbury, Ph.D., M.S.P.H., Program Director, Clinical and Translational Epidemiology Branch, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences (DCCPS), NCI. [PDF, HTML]
Session I: Where are we now and where do we need to go?
8:45 a.m. – 9:15 a.m. Cancer Pharmacogenomics: Development, Science, and Translation

Richard M. Weinshilboum, M.D., Chair, Division of Clinical Pharmacology and Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine [PDF, HTML]
9:15 a.m. – 9:45 a.m. Challenges in the Design and Conduct of Clinical Pharmacogenomic Studies

Mark J. Ratain, M.D., Leon O. Jacobson Professor of Medicine, Chairman of the Committee on Clinical Pharmacology, and Associate Director for Clinical Sciences, Cancer Research Center, University of Chicago [PDF, HTML]
9:45 a.m. – 10:00 a.m. Break
Session II: How are we going to get there?
10:00 a.m. – 10:30 a.m. Interventional Pharmacogenetics: Moving the Science Into Practice

Howard McLeod, Pharm.D., Fred N. Eshelman Distinguished Professor Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, and Director, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill [PDF, HTML]
10:30 a.m. – 11:00 a.m. Applications of Cancer Pharmacogenomics in a Naturalistic Setting

Robert S. Epstein, M.D., M.S., Chief Medical Officer and Senior Vice President of Medical and Analytical Affairs, Medco Health Solutions, Inc. [PDF, HTML]
11:00 a.m. – 11:30 a.m. Genome-Guided Clinical Trials to Evaluate the Clinical Utility of Cancer Pharmacogenomics

Geoffrey S. Ginsburg, M.D., Ph.D., Director, Institute for Genome Sciences and Policy, Duke University [PDF, HTML]
11:30 a.m. – 12:00 p.m. Panel Discussion

Moderator:
Richard L. Schilsky, M.D., Professor of Medicine and Associate Dean for Clinical Research, University of Chicago

Panelists:
David A. Flockhart, M.D., Ph.D., Chief, Division of Clinical Pharmacology, Indiana University School of Medicine. [PDF, HTML]

Geoffrey Liu, M.D., M.Sc., Alan B. Brown Chair in Molecular Genomics and Scientist, Division of Applied Molecular Oncology, Princess Margaret Hospital, University of Toronto

Cornelia Ulrich, Ph.D., Member, Cancer Prevention Program, Fred Hutchinson Cancer Research Center. [PDF, HTML]
12:00 p.m. – 1:00 p.m. Lunch
Session III: Breakout Sessions
1:00 p.m. – 1:20 p.m. Trans-NCI PPWG Recommendations and Charge to the Group

Andrew N. Freedman, Ph.D., Chief, Clinical and Translational Epidemiology Branch, DCCPS, NCI
1:20 p.m. – 3:00 p.m. Working Group Breakout Sessions

Each breakout group will be charged with evaluating the Trans-NCI PPWG’s recommendations on moving an NCI research agenda forward in the areas of pharmacoepidemiology and pharmacogenomics.

Working Group A

Moderators:
Rochelle M. Long, Ph.D., Chief, Pharmacological and Physiological Sciences Branch, Division of Pharmacology, Physiology, and Biological Chemistry, National Institute of General Medical Sciences (NIGMS)

Robert L. Davis, M.D., M.P.H., Director, Center for Health Research Southeast, Kaiser Permanente of Georgia

Working Group B

Moderators:
Lawrence J. Lesko, Ph.D., Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration (FDA)

Sheila R. Weiss Smith, Ph.D., Professor, Pharmaceutical Health, Services Research Department, University of Maryland, Baltimore

Working Group C

Moderators:
Muin J. Khoury, M.D., Ph.D., Director, Office of Public Health Genomics, Centers for Disease Control and Prevention (CDC)

Lori M. Minasian, M.D., Chief, Community Oncology and Prevention Trials Research Branch, Division of Cancer Prevention, NCI
3:00 p.m. – 3:20 p.m. Break
Session IV: Breakout Session Reports
3:20 p.m. – 5:30 p.m. Working Group Presentations and General Discussion
5:30 p.m. – 5:45 p.m. Closing Remarks

Andrew N. Freedman, Ph.D., Chief, Clinical and Translational Epidemiology Branch, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences (DCCPS), NCI

Last Updated: 11 Jun 2012

Division of Cancer Control and Population Sciences National Cancer Institute Department of Health and Human Services National Institutes of Health USA.gov